BOSQF:OTC-Better Plant Sciences Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 0.09

Change

0.00 (0.00)%

Market Cap

USD 9.34M

Volume

3.29M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Better Plant Sciences Inc., through its subsidiaries, develops, markets, and sells of plant-based products for health and wellness. The company offers cosmetic and therapeutic products made of cannabis sativa hemp root oil and essential oils. It also develop and acquire intellectual property for plant-based products. The company offers plant-based skin care products under Urban Juve brand name; cannabis wellness products under Wright & Well and Jack n Jane brands; botanicals, fruit extracts, and spices under the UJ Beverages brand. The company was formerly known as The Yield Growth Corp. and changed its name to Better Plant Sciences Inc. in August 2020. Better Plant Sciences Inc. was incorporated in 2014 and is headquartered in Vancouver, Canada.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-18 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MKKGY MERCK Kommanditgesellschaft au..

+0.24 (+0.54%)

USD97.09B 30.68 18.52
MKGAF MERCK Kommanditgesellschaft au..

+1.63 (+0.73%)

USD96.93B 30.76 18.52
TKPHF Takeda Pharmaceutical Company ..

-0.20 (-0.72%)

USD44.64B 11.77 0.07
ESALF Eisai Co. Ltd

-1.01 (-1.40%)

USD20.64B 39.39 0.17
ESALY Eisai Co. Ltd

-0.57 (-0.80%)

USD20.49B 38.98 0.17
SGIOF Shionogi & Co. Ltd

-0.80 (-1.18%)

USD20.48B 19.36 0.11
SGIOY Shionogi & Co. Ltd

-0.28 (-1.63%)

USD20.48B 19.26 0.11
SFOSF Shanghai Fosun Pharmaceutical ..

+0.16 (+3.29%)

USD18.44B 17.67 2.44
TEVJF Teva Pharmaceutical Industries..

N/A

USD10.91B 900.00 16.02
MTZPY Mitsubishi Tanabe Pharma Corpo..

N/A

USD10.43B 79.00 0.21

ETFs Containing BOSQF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -30.79% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.79% N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain 55.00% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 55.00% N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -25.08% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.08% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 37.13% N/A N/A N/A N/A
Risk Adjusted Return -67.54% N/A N/A N/A N/A
Market Capitalization 9.34M N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 3.46 N/A N/A N/A N/A
Price / Cash Flow Ratio -0.78 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -1,068.95% N/A N/A N/A N/A
Return on Assets -122.30% N/A N/A N/A N/A
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 1.80 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.